Capella Bioscience

Monoclonal antibodies (mAbs) in oncology and autoimmune disease.

placeLondon, England, United Kingdom calendar_todayFounded 2014 groups3 employees language capellabioscience.com

Registered entities

Investor mix

10 investors on record; lead investors include Osage University Partners, Advent Life Sciences, Medicxi; 1 has since exited.

Investor typeCountShare
Venture capital550%
Other / undisclosed550%
Coming soon